Detalles de la búsqueda
1.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Nat Med
; 30(5): 1330-1338, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38653864
2.
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
bioRxiv
; 2023 Aug 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37609261
3.
Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
Front Immunol
; 13: 965331, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131935
Resultados
1 -
3
de 3
1
Próxima >
>>